Atea Pharmaceuticals, Inc.
AVIRNASDAQHealthcare● Active
$4.32
+$0.07(+1.65%)
Market Cap$345717068
P/E Ratio—
52W High$6.45
52W Low$2.78
Atea Pharmaceuticals, Inc. (AVIR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AVIR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.57
Est. -$0.60 · +5.0%
Revenue
—
Est. $0.02B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
AVIR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.56 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.60 | -$0.57 | +5.0% | — | $0.02B | — |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.49 | -$0.57 | -16.3% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.46 | -$0.53 | -15.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.46 | -$0.44 | +4.3% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.56 | -$0.40 | +28.6% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.35 | -$0.40 | -14.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.49 | -$0.37 | +24.5% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.56
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.57
EPS Est.
-$0.60
EPS Surpr.
+5.0%
Revenue
—
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.57
EPS Est.
-$0.49
EPS Surpr.
-16.3%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.53
EPS Est.
-$0.46
EPS Surpr.
-15.2%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.46
EPS Surpr.
+4.3%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.56
EPS Surpr.
+28.6%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.35
EPS Surpr.
-14.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.37
EPS Est.
-$0.49
EPS Surpr.
+24.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q3 FY2028 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q2 FY2028 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2028 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q4 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q3 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +5.0% | $5.41 | $5.50 | +1.66% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -16.3% | $4.98 | $5.30 | +6.43% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -15.2% | $3.38 | $3.50 | +3.55% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +4.3% | $3.49 | $3.46 | -0.86% |
| ▲ Q2 FY2025 | May 12, 2025 | +28.6% | $2.72 | $2.96 | +8.82% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -14.3% | $3.01 | $3.00 | -0.33% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +24.5% | $3.58 | $3.44 | -3.91% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +36.8% | $3.29 | $3.27 | -0.61% |
Q2 FY2026+1.66%
Report Date
May 12, 2026
EPS Beat/Miss
+5.0%
Price Before
$5.41
Price After
$5.50
Q1 FY2026+6.43%
Report Date
Mar 5, 2026
EPS Beat/Miss
-16.3%
Price Before
$4.98
Price After
$5.30
Q4 FY2025+3.55%
Report Date
Nov 12, 2025
EPS Beat/Miss
-15.2%
Price Before
$3.38
Price After
$3.50
Q3 FY2025-0.86%
Report Date
Aug 7, 2025
EPS Beat/Miss
+4.3%
Price Before
$3.49
Price After
$3.46
Q2 FY2025+8.82%
Report Date
May 12, 2025
EPS Beat/Miss
+28.6%
Price Before
$2.72
Price After
$2.96
Q1 FY2025-0.33%
Report Date
Mar 6, 2025
EPS Beat/Miss
-14.3%
Price Before
$3.01
Price After
$3.00
Q4 FY2024-3.91%
Report Date
Nov 7, 2024
EPS Beat/Miss
+24.5%
Price Before
$3.58
Price After
$3.44
Q3 FY2024-0.61%
Report Date
Aug 7, 2024
EPS Beat/Miss
+36.8%
Price Before
$3.29
Price After
$3.27
Avg Beat Reaction+1.02%
Avg Miss Reaction+3.22%
Beat Rate5 / 8 quarters
Largest Move+8.82% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AVIR ends December
Atea Pharmaceuticals, Inc. (AVIR) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.57 — beating the analyst consensus of $-0.60 by +5.0%. The next AVIR earnings date is expected around September 1, 2026.
Each quarter, investors track AVIR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AVIR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AVIR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AVIR earnings · 5 questionsAtea Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. AVIR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AVIR historically reports after market close (AMC).
AVIR earnings datewhen is AVIR earningsAVIR next earnings datewhen does AVIR report earningsAVIR earnings calendar
▸ Source: FMP · Atea Pharmaceuticals, Inc. SEC filings · US GAAP · Atea Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026